

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM639536

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	INTELLECTUAL PROPERTY SECURITY AGREEMENT		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
REZOLUTE, INC.		04/14/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	SLR INVESTMENT CORP., AS COLLATERAL AGENT		
Street Address:	500 PARK AVENUE, 3RD FLOOR		
City:	NEW YORK		
State/Country:	NEW YORK		
Postal Code:	10022		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5603038	REZOLUTE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7145401235		
Email:	IPDOCKET@LW.COM, KRISTIN.AZCONA@LW.COM		
Correspondent Name:	LATHAM & WATKINS LLP		
Address Line 1:	650 TOWN CENTER DRIVE, 20TH FLOOR		
Address Line 4:	COSTA MESA, CALIFORNIA 92626		
ATTORNEY DOCKET NUMBER:	054439-62		
NAME OF SUBMITTER:	KRISTIN J AZCONA		
SIGNATURE:	/KJA/		
DATE SIGNED:	04/15/2021		
Total Attachments: 7			
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page1.tif			
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page2.tif			
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page3.tif			
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page4.tif			
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page5.tif			

OP \$40.00 5603038

source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page6.tif
source=Rezolute - SLR - Intellectual Property Security Agreement Executed Version_122261744_5_0#page7.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") dated as of April 14, 2021, is made by REZOLUTE, INC., a Delaware corporation ("Grantor"), in favor of SLR INVESTMENT CORP., a Maryland corporation, in its capacity as collateral agent (in such capacity, "Agent") for the Lenders (as defined below).

RECITALS

A. Grantor has entered into a Loan and Security Agreement dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement") with certain financial institutions party thereto (the "Lenders") and Agent. All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held (collectively, the "Copyrights");

(b) Any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know how, operating manuals now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, re-examination certificates, utility models, extensions and continuations-in-part of the same, now or hereafter existing, created, acquired or held, including without limitation the patents and patent applications set forth on Exhibit A attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit B attached hereto (collectively, the "Trademarks");

(f) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or mask works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, or Patents;
and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include (x) rights held under a license that are not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment is effective under Section 9-406, 9-407, 9-408 or 9-409 of the Code (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity); or (y) any "intent to use" trademark applications for which a statement of use has not been filed (but only until such statement is filed) to the extent that the assignment of or grant of a security interest in such rights or property would cause a material adverse consequence to the Borrower's ownership or use of such rights or property.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.


7. Electronic Execution of Certain Other Documents. The words "execution," "execute", "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

REZOLUTE, INC., a Delaware corporation

DocuSigned by:

By: _____
Name: Nevan C. Elam
Title: CEO

AGENT:

SLR INVESTMENT CORP., a Maryland corporation


DocuSigned by:

By: _____
Name: Anthony Storino
Title: Authorized Signatory

EXHIBIT A

Patents

No.	Title	Application Number Application Date	Publication Number Publication Date	Owner
1	SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES	14324734 7/7/2014	US9439864B2 9/13/2016	Rezolute Inc.
2	SITE-SPECIFIC INSULIN-POLYMER CONJUGATES	14691855 4/21/2015	US9789196B2 10/17/2017	Rezolute Inc.
3	USE OF HYDROPHOBIC ORGANIC ACIDS TO INCREASE HYDROPHOBICITY OF PROTEINS AND PROTEIN CONJUGATES	14954591 11/30/2015	US10046058B2 8/14/2018	Rezolute Inc.
4	SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES	14974201 12/18/2015	US9532953B2 1/3/2017	Rezolute Inc.
5	AMINE PEGYLATION METHODS FOR THE PREPARATION OF SITE-SPECIFIC PROTEIN CONJUGATES	15158898 5/19/2016	US10220075B2 3/5/2019	Rezolute Inc.
6	SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES	15357784 11/21/2016	US10137089B2 11/27/2018	Rezolute Inc.
7	COILED TUBE EMULSIFICATION SYSTEMS	15705818 9/15/2017	US10561620B2 2/18/2020	Rezolute Inc.
8	USE OF HYDROPHOBIC ORGANIC ACIDS TO INCREASE HYDROPHOBICITY OF PROTEINS AND PROTEIN CONJUGATES	16032952 7/11/2018	US10702611B2 7/7/2020	Rezolute Inc.
9	COILED TUBE EMULSIFICATION METHODS	16716886 12/17/2019	US20200129443A1 4/30/2020	Rezolute Inc.
10	CRYSTALLINE FORMS OF PLASMA KALLIKREIN INHIBITORS	16922064 7/7/2020	US20210009525A1 1/14/2021	Rezolute Inc. and Activesite Pharmaceuticals, Inc.
11	PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS	16922080 7/7/2020	US20210009526A1 1/14/2021	Rezolute Inc. and Activesite Pharmaceuticals, Inc.
12	MATERIALS AND METHODS FOR PREPARING PROTEIN-POLYMER CONJUGATES	2003553570 8/22/2006	US9040664B2 5/26/2015	Rezolute Inc. and PR Pharmaceuticals, Inc.

No.	Title	Application Number Application Date	Publication Number Publication Date	Owner
13	Plasma Kallikrein Inhibitors for ARDS	63015062 4/24/2020		Rezolute Inc. and PR Pharmaceuticals, Inc.

EXHIBIT B

Trademarks

No.	Trademark	Database	Status	Application Number Application Date	Registration Number Registration Date	Owner Name
1	REZOLUTE REZOLUTE	U.S. Federal	REGISTERED	87695088 11/22/2017	5603038 11/6/2018	REZOLUTE, INC.